BIGG

Início > Guias GRADE > Resultado da busca

Resultados: 3

Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy

England. National Institute for Health and Care Excellence.
People with BRCA mutation-positive HER2‑negative high-risk early breast cancer usually have chemotherapy followed by surgery (neoadjuvant chemotherapy), or surgery followed by chemotherapy (adjuvant chemotherapy). Clinical trial evidence shows that, compared with placebo, olaparib after neoadjuvant or...
Proteína BRCA1, Neoplasias de Mama Triplo Negativas/tratamento farmacológico, Mutação em Linhagem Germinativa/efeitos dos fármacos, Inibidores da Síntese de Ácido Nucleico/uso terapêutico
Texto completo

Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer

England. National Institute for Health and Care Excellence.
This evaluation uses new cost-effectiveness estimates to update olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (NICE technology appraisal guidance TA831). No new clinical evidence was reviewed. Treatments for BRCA mutation-positive hormone-relapsed meta...
Neoplasias da Próstata/tratamento farmacológico, Mutação/efeitos dos fármacos, Proteína BRCA1, Antineoplásicos Hormonais/uso terapêutico
Texto completo

Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer

England. National Institute for Health and Care Excellence.
Evidence-based recommendations on olaparib (Lynparza) for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer in adults. Commercial arrangement There is a simple discount patient access scheme for olaparib. NHS organisations can get details on the Commercial Access and ...
Neoplasias da Próstata/tratamento farmacológico, Proteína BRCA1, Mutação, Antineoplásicos/uso terapêutico
Texto completo